Special Issue: Metabolomic Biomarkers
Published 09 November, 2017
Massively publicized efforts in DNA and protein based biomarkers have highlighted the importance of biomarkers throughout the clinical ecosystem. Despite these advances, it is clear that additional progress across a range of ‘omics’ will be needed to meet the clinical demand for biomarkers. Recently, huge advances in the computational and experimental underpinnings of metabolomics (the comprehensive analysis of all metabolites in a system) have made tremendous strides. Consequently, metabolomic biomarkers are poised to rapidly emerge as critical components of clinical decision-making. Compared to classical diagnostic approaches and conventional clinical biomarkers, metabolites may offer improved sensitivity and specificity. Our focus in this special issue is to highlight:
-
Major advances in metabolomics that are enabling biomarker development and application
-
Emerging metabolomic biomarkers
-
Emerging platforms for metabolomic biomarker discovery and clinical application
-
Ongoing challenges in metabolomics for biomarker discovery and deployment
-
Comparisons of the challenges in metabolomics biomarker development relative to other ‘omics’
In addition to traditional articles and reviews, we are also soliciting nano-publications describing/reviewing particular biomarker candidates.
Special Issue Guest Editors:
Parag Mallick
Stanford University, Palo Alto, CA, USA
Email: paragm@stanford.edu
Jonathan Katz
University of Southern California, Los Angeles, CA, USA
Email: katzj@usc.edu
Paper submission due:
31 July 2018